EUDA Launches First Stem Cell Therapy Platform, Expands into China Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Should l Buy EUDA?
Source: Globenewswire
- Strategic Acceleration: EUDA Health Holdings has launched a comprehensive stem cell therapy platform in Shenzhen, China, marking a significant acceleration in its longevity and regenerative medicine strategy, which is expected to enhance the company's competitiveness in the rapidly growing health market.
- Facility Upgrade: The company is upgrading Shenzhen Inno's cGMP facility to integrate advanced stem cell technologies from Japan, aimed at supporting immune cell therapies and the development of new treatments, thereby strengthening its technical capabilities in regenerative medicine.
- New Clinic Establishment: EUDA, in partnership with KB International, has established the first longevity clinic in Shenzhen, offering personalized AI-guided life cycle management and advanced stem cell therapies, which is expected to attract a customer base interested in longevity healthcare.
- Market Leadership: EUDA aims to meet the healthcare needs of over 1.8 billion people, particularly in rapidly aging markets, through innovative health solutions, further solidifying its market leadership in non-invasive healthcare.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EUDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EUDA
About EUDA
EUDA Health Holdings Limited is a health technology company. The Company operates a southeast Asian digital healthcare ecosystem. Its unified artificial intelligence platform assesses patients' medical history, triages conditions, digitally connects patients with clinicians, and predicts optimal treatment outcomes. Its holistic approach supports patients throughout all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. Its medical urgent care services provide healthcare assistance and medical evacuation to individual and corporate clients. Its property management service covers the management of properties, such as condominiums and shopping malls. Its services include e-triage, GP consult, e-medical certificates, and medical prescriptions. Its EUDA platform provides medical services from primary to post-surgery care and ongoing preventive healthcare for clients, regardless of the level of healthcare required.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
See More
EUDA Health Holdings Lowers Warrant Exercise Price to $4
- Warrant Amendment: EUDA has amended its agreement with Streeterville Capital to reduce the warrant exercise price from $6 to $4 per share, which is expected to enhance investor willingness to exercise the warrants, thereby improving the company's liquidity.
- Forced Exercise Condition Adjustment: The minimum closing price required for a forced exercise has been lowered from $7.50 to $6.00, which may encourage more investors to exercise their warrants during market fluctuations, further optimizing the company's capital structure.
- Strengthened Market Positioning: EUDA focuses on the non-invasive healthcare market in Singapore, Malaysia, and China, aiming to address the healthcare needs of over 1.8 billion people, positioning itself strategically in the rapidly growing longevity sector amid accelerating demographic shifts.
- Business Diversification: In addition to healthcare, EUDA operates a property management business in Singapore, showcasing its capability to diversify across multiple sectors, aiming to enhance overall market competitiveness through varied business operations.
See More
EUDA Launches Nationwide Stem Cell Extraction Platform, Supporting 200,000 Units Storage
- Platform Launch: EUDA has launched a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China, marking a significant advancement in its stem cell strategy aimed at enhancing service capabilities in emerging markets.
- Partnerships Established: Collaborating with Shenzhen Inno Immune and Wuhan Kaien Hospital ensures cell processing and storage capabilities in Southern and Central China, with initial designed storage capacities of 50,000 and 200,000 units respectively, thereby enhancing clinical service coverage.
- National Network Development: EUDA is building a network of approximately 200 clinical preparation and treatment clinics across more than 20 provinces through partnerships with Guangdong Wanhai Cell Biotechnology and Shunfeng Cold Chain Logistics, ensuring convenient access for patients to undergo stem cell extraction and subsequent treatments.
- Strategic Vision: The CEO of EUDA stated that this platform will transform how regenerative medicine is accessed and delivered in China by integrating extraction, storage, and logistics into a comprehensive scalable infrastructure to meet the rapidly growing demands of the aging market.
See More
EUDA Launches Nationwide Stem Cell Extraction and Storage Platform, Supporting 200,000 Patients
- Platform Launch: EUDA has introduced a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China, marking a significant advancement in the company's stem cell strategy aimed at enhancing healthcare service capabilities in the Asia-Pacific region.
- Partnerships Established: Collaborating with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital ensures cell processing and storage capabilities in Southern and Central China, with initial designed capacities of 50,000 and 200,000 patient cell units respectively, thereby enhancing clinical service coverage.
- National Network Development: By partnering with Guangdong Wanhai Cell Biotechnology Co., Ltd. and Shunfeng Cold Chain Logistics Co., Ltd., EUDA has established a nationwide clinical access layer supporting a network of approximately 200 treatment clinics, ensuring convenient stem cell extraction and clinical delivery for patients.
- Strategic Vision: EUDA's CEO stated that this platform will transform how regenerative medicine is accessed and delivered in China, creating an integrated ecosystem that connects extraction, storage, and clinical delivery to meet the demands of the rapidly growing aging market.
See More
EUDA Launches Helixé 2.0 with 20% Enhanced Formula Strength
- Formula Upgrade: EUDA Helixé 2.0 features a 20% increase in New Zealand-sourced deer placenta powder, enhancing the dosage from 100 mg to 120 mg, which solidifies its positioning as a high-potency supplement and is expected to attract health-conscious consumers.
- Technological Innovation: The new product utilizes advanced freeze-drying and nitrogen encapsulation technologies, significantly improving nutrient stability and absorption efficiency, which is anticipated to enhance user experience and strengthen market competitiveness.
- Global Market Expansion: EUDA Helixé 2.0 has obtained New Zealand Halal certification, marking its formal entry into Muslim markets across Southeast Asia and the Middle East, which is expected to drive sales growth on a global scale.
- Brand Image Enhancement: The newly introduced proprietary bottle design not only enhances product protection and shelf presence but also strengthens brand identity, which is expected to further increase consumer brand loyalty.
See More
EUDA Launches Helixé 2.0 with 20% Enhanced Formula Strength
- Formula Upgrade: EUDA Helixé 2.0 features a 20% increase in New Zealand-sourced deer placenta powder, enhancing the dosage from 100 mg to 120 mg, which solidifies its positioning as a high-potency vitality supplement and is expected to attract health-conscious consumers.
- Technological Innovation: The new product utilizes advanced ingredient preservation and delivery technologies, including freeze-drying and nitrogen encapsulation, significantly improving nutrient stability and absorption efficiency, thereby enhancing user experience and competitive market positioning.
- Global Market Expansion: EUDA Helixé 2.0 has obtained New Zealand Halal certification, marking its formal entry into Muslim markets across Southeast Asia and the Middle East, which is expected to drive sales growth globally and further expand market share.
- Brand Image Enhancement: The newly designed EUDA Helixé bottle not only reflects the product's premium positioning but also enhances product protection and brand recognition, which is anticipated to increase consumer purchase intent and brand loyalty.
See More
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
See More
EUDA Health Holdings Lowers Warrant Exercise Price to $4
- Warrant Amendment: EUDA has amended its agreement with Streeterville Capital to reduce the warrant exercise price from $6 to $4 per share, which is expected to enhance investor willingness to exercise the warrants, thereby improving the company's liquidity.
- Forced Exercise Condition Adjustment: The minimum closing price required for a forced exercise has been lowered from $7.50 to $6.00, which may encourage more investors to exercise their warrants during market fluctuations, further optimizing the company's capital structure.
- Strengthened Market Positioning: EUDA focuses on the non-invasive healthcare market in Singapore, Malaysia, and China, aiming to address the healthcare needs of over 1.8 billion people, positioning itself strategically in the rapidly growing longevity sector amid accelerating demographic shifts.
- Business Diversification: In addition to healthcare, EUDA operates a property management business in Singapore, showcasing its capability to diversify across multiple sectors, aiming to enhance overall market competitiveness through varied business operations.
See More
EUDA Launches Nationwide Stem Cell Extraction Platform, Supporting 200,000 Units Storage
- Platform Launch: EUDA has launched a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China, marking a significant advancement in its stem cell strategy aimed at enhancing service capabilities in emerging markets.
- Partnerships Established: Collaborating with Shenzhen Inno Immune and Wuhan Kaien Hospital ensures cell processing and storage capabilities in Southern and Central China, with initial designed storage capacities of 50,000 and 200,000 units respectively, thereby enhancing clinical service coverage.
- National Network Development: EUDA is building a network of approximately 200 clinical preparation and treatment clinics across more than 20 provinces through partnerships with Guangdong Wanhai Cell Biotechnology and Shunfeng Cold Chain Logistics, ensuring convenient access for patients to undergo stem cell extraction and subsequent treatments.
- Strategic Vision: The CEO of EUDA stated that this platform will transform how regenerative medicine is accessed and delivered in China by integrating extraction, storage, and logistics into a comprehensive scalable infrastructure to meet the rapidly growing demands of the aging market.
See More
EUDA Launches Nationwide Stem Cell Extraction and Storage Platform, Supporting 200,000 Patients
- Platform Launch: EUDA has introduced a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China, marking a significant advancement in the company's stem cell strategy aimed at enhancing healthcare service capabilities in the Asia-Pacific region.
- Partnerships Established: Collaborating with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital ensures cell processing and storage capabilities in Southern and Central China, with initial designed capacities of 50,000 and 200,000 patient cell units respectively, thereby enhancing clinical service coverage.
- National Network Development: By partnering with Guangdong Wanhai Cell Biotechnology Co., Ltd. and Shunfeng Cold Chain Logistics Co., Ltd., EUDA has established a nationwide clinical access layer supporting a network of approximately 200 treatment clinics, ensuring convenient stem cell extraction and clinical delivery for patients.
- Strategic Vision: EUDA's CEO stated that this platform will transform how regenerative medicine is accessed and delivered in China, creating an integrated ecosystem that connects extraction, storage, and clinical delivery to meet the demands of the rapidly growing aging market.
See More
EUDA Launches Helixé 2.0 with 20% Enhanced Formula Strength
- Formula Upgrade: EUDA Helixé 2.0 features a 20% increase in New Zealand-sourced deer placenta powder, enhancing the dosage from 100 mg to 120 mg, which solidifies its positioning as a high-potency supplement and is expected to attract health-conscious consumers.
- Technological Innovation: The new product utilizes advanced freeze-drying and nitrogen encapsulation technologies, significantly improving nutrient stability and absorption efficiency, which is anticipated to enhance user experience and strengthen market competitiveness.
- Global Market Expansion: EUDA Helixé 2.0 has obtained New Zealand Halal certification, marking its formal entry into Muslim markets across Southeast Asia and the Middle East, which is expected to drive sales growth on a global scale.
- Brand Image Enhancement: The newly introduced proprietary bottle design not only enhances product protection and shelf presence but also strengthens brand identity, which is expected to further increase consumer brand loyalty.
See More
EUDA Launches Helixé 2.0 with 20% Enhanced Formula Strength
- Formula Upgrade: EUDA Helixé 2.0 features a 20% increase in New Zealand-sourced deer placenta powder, enhancing the dosage from 100 mg to 120 mg, which solidifies its positioning as a high-potency vitality supplement and is expected to attract health-conscious consumers.
- Technological Innovation: The new product utilizes advanced ingredient preservation and delivery technologies, including freeze-drying and nitrogen encapsulation, significantly improving nutrient stability and absorption efficiency, thereby enhancing user experience and competitive market positioning.
- Global Market Expansion: EUDA Helixé 2.0 has obtained New Zealand Halal certification, marking its formal entry into Muslim markets across Southeast Asia and the Middle East, which is expected to drive sales growth globally and further expand market share.
- Brand Image Enhancement: The newly designed EUDA Helixé bottle not only reflects the product's premium positioning but also enhances product protection and brand recognition, which is anticipated to increase consumer purchase intent and brand loyalty.
See More
